Finding the right treatment for Alzheimer’s disease can often feel like a game of trial and error. Many patients are prescribed medications to manage symptoms like depression, anxiety, or agitation, but responses vary significantly from person to person.
For years, scientists have sought a way to predict which treatments are most likely to be effective on an individual basis.
Researchers at Johns Hopkins Medicine believe that lab-grown miniature brain tissues, or organoids, could eventually provide this insight. Their study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, highlights a future where treatment choices might be guided by living models created from a patient’s own cells.
The team began with a simple blood sample. They reprogrammed the blood cells to function like stem cells, which can then develop into various types of tissue. Using these cells, they produced hundreds of tiny hindbrain organoids from both Alzheimer’s patients and healthy volunteers.
Although these organoids are only a few millimeters in size, they contain living nerve cells that self-organize into structures resembling parts of the human brain. This setup allows scientists to observe disease processes in ways that aren’t possible inside a living person.
The researchers focused on escitalopram, a common antidepressant in the SSRI class. These medications are frequently used because neuropsychiatric symptoms tend to affect nearly everyone with Alzheimer’s at some point during the illness.
When escitalopram was applied to the organoids, responses varied. Some organoids showed improved serotonin activity and better communication between nerve cells, while others exhibited little to no change. This variability suggests that differences in biology among patients could explain why some respond to treatment while others do not.
The team also analyzed extracellular vesicles released by the organoids — tiny particles that act like delivery packages, transporting proteins and molecular signals between cells. Because these vesicles reflect the state of the brain tissue, they could become useful markers for disease activity.
They found that several proteins vital for healthy nerve signaling were decreased in organoids derived from Alzheimer’s patients. In organoids that responded to treatment, some of these proteins increased, offering a molecular measure of treatment effectiveness.
Looking ahead, scientists hope to develop more complex organoids that include blood vessel-like structures and immune cells, making them even more similar to actual human brain tissue. They also believe that extracellular vesicles might eventually be used as a simple, non-invasive liquid biopsy — aiding in early diagnosis, determining disease stages, and identifying different Alzheimer’s subtypes.
This research marks an important step toward personalized medicine for Alzheimer’s. It shows how patient-specific brain organoids could help explain why some people respond to medications while others don’t.
However, it’s important to note that the work has been done in laboratory tissue models, not directly in patients. More research and clinical trials are needed before this approach can be adopted in medical settings.
If these findings are confirmed in future studies, brain organoids and extracellular vesicles could become invaluable tools for tailoring treatments, diagnosing Alzheimer’s earlier, and tracking its progression.
For those interested in Alzheimer’s disease, consider exploring studies on how dietary antioxidants might offer protective benefits or how eating habits could influence the risk of developing the condition.
Additionally, recent research suggests that oral cannabis extracts may help alleviate symptoms, and Vitamin E could potentially play a role in Parkinson’s disease prevention.
Source: Johns Hopkins Medicine.